Frontlight ResearchEarly access
Hypertrophic cardiomyopathy trials in Canada
1 of 4 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Enrolling by invitationOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
- Where
- Edmonton, Halifax, Montreal, Québec, Winnipeg
- Age
- 18 years to 85 years
- People
- 900 worldwide
- Run by
- Cytokinetics
See details and how to joinNCT04848506 · EU 2023-508963-58-00